Fixed Low-Dose Drug Combination for the Treatment of Hypertension

Archives of Family Medicine

Volumn 7, Issue 4, 1998, Pages 370-376

  Chrysant, Steven G ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

DRUG COMBINATION; HUMAN; HYPERTENSION; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION;

EID: 0032109422     PISSN: 10633987     EISSN: None     Source Type: Journal    
DOI: 10.1001/archfami.7.4.370     Document Type: Review

References (100)

1. Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1993;153:154-183.
2. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914-921.
3. Messerli FH. Combination therapy in hypertension. J Hum Hypertens. 1992;6(suppl 2):S19-S21.
4. Chalmers J. The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens. 1993;15:1299-1313.
5. Sica DA. Fixed-dose combination antihypertensive drugs. Drugs. 1994;48:16-24.
6. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med. 1996;156: 1969-1978.
7. Neutel JM, Black HR, Weber MA. Combination therapy with diuretics: an evolution of understanding. Am J Med. 1996;101(suppl 3A): 61S-70S.
8. Abernethy DR. Pharmacological properties of combination therapies for hypertension. Am J Hypertens. 1997;10:13S-16S.
9. Frishman WH. Results of hypertension treatment with low-dose combination of a β-adrenergic blocker with a diuretic. Am J Hypertens. 1997;10:17S-23S.
10. Chrysant SG, Luu TM. Effects of amiloride on arterial pressure and renal function. J Clin Pharmacol. 1980;20:322-327.
11. McKenna TJ, Donohoe JF, Brien TG, Healy JJ, Canning BSEJ, Muldowney EP. Potassium-sparing agents during diuretic therapy in hypertension. BMJ. 1971;2:739-741.
12. Chrysant SG, Ganousis L, Chrysant C. Hemodynamic and metabolic effects of hypomagnesemia in spontaneously hypertensive rats. Cardiology. 1988;75:81-89.
13. Altura BM, Altura BT, Ising H, Gunther T. Magnesium deficiency and hypertension: correlation between magnesium deficient diets and microcirculatory changes in situ. Science. 1984; 223:1315-1317.
14. Whang R, Chrysant SG, Dillard BL, Smith WJ, Fryer A. Hypomagnesemia and hypokalemia in 1000 treated ambulatory hypertensive patients. J Am Coll Nutr. 1982;1:317-322.
15. Dyckner T, Wester PO. Effect of magnesium on blood pressure. BMJ. 1983;286:1847-1849.
16. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOHMS). Circulation. 1995;91:698-706.
17. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents: Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 1997;95:2007-2014.
18. Grimm RH, Grandits GA, Cutler JA, et al. Relationships of quality of life measures to long-term lifestyle and drug treatment in the mild hypertension study. Arch Intern Med. 1997;157: 638-648.
19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
20. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients (STOP-Hypertension). Lancet. 1991;338:1281-1285.
21. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;204:405-412.
22. Materson BJ, Oster JR, Michael UF, et al. Dose response of chlorthalidone in patients with mild hypertension: efficacy of a lower dose. Clin Pharmacol Ther. 1978;24:192-198.
23. Chrysant SG, Neller GK, Dillard BL, Frohlich ED. Effects of diuretics on lipid metabolism in patients with essential hypertension. Angiology. 1976;27:707-711.
24. Ames RP, Hill P. Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indexes. Clin Sci. 1978;55: 311S-314S.
25. Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther. 1977;22:499-504.
26. Whitsett TL, Chrysant SG. Diuretics. In: Papper S, ed. Sodium: Its Biologic Significance. Boca Raton, Fla: CRC Press Inc; 1982:177-203.
27. Amery A, Berthaux P, Bulpitt C, et al. Glucose intolerance during diuretic therapy: results of a trial by the European Working Party on hypertension in the elderly. Lancet. 1978;1:681-683.
28. McKenney JM, Goodman RP, Wright JT, Rifai N, Aycock DG, King ME. The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium and lipoproteins. Pharmacotherapy. 1986;6:179-184.
29. Chrysant SG, Chappel C, Farnham DJ, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol. 1992;32:61-65.
30. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886-1892.
31. Beling S, Vukovich RA, Neiss ES, et al. Long-term experience with indapamide. Am Heart J. 1983;106:258-262.
32. Meyer-Sabellek W, Gotzen R, Heitz J, et al. Serum lipoprotein levels during long-term treatment of hypertension with indapamide. Hypertension. 1985;7(suppl II):170-174.
33. Levine B, Lee W, Boyd G, et al. Conversion from 2.5 mg to 1.25 mg indapamide in patients with mild to moderate hypertension. J Fam Pract. 1995;41:75-80.
34. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274: 620-625.
35. Garrett BN, Kaplan NM. Plasma renin activity suppression: duration after withdrawal from β-adrenergic blockade. Arch Intern Med. 1980; 140:1316-1318.
36. Frishman W, Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs, part 2: physiologic and metabolic effects. Am Heart J. 1979;97:797-807.
37. Kubik M, Kendall M, Ebbutt A, John V. Metoprolol with and without chlorthalidone in hypertension. Clin Pharmacol Ther. 1979;25:25-32.
38. Chrysant SG, Brown JL, Hagstrom D. Antihypertensive and metabolic effects of hydrochlorothiazide, amiloride-hydrochlorothiazide and timolol. J Clin Pharmacol. 1983;23:147-154.
39. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J. 1995;130:359-366.
40. Bakris GL, Wilson DM, Burnett JC Jr. The renal forearm and humoral responses to standing in the presence and absence of propranolol. Circulation. 1986;74:1061-1065.
41. Freis ED, Materson BJ, Flamenbaum W, Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol or hydrochlorothiazide alone for the treatment of hypertension: evaluation of the renin angiotensin: from the Cooperative Studies Program, Medical Research Service of the Veteran Administration. Am J Med. 1983;74:1029-1041.
42. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol. 1983;52:1230-1237.
43. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension, II: results of long-term therapy. JAMA. 1982;248:2004-2011.
44. Trauby M, Rabinov M, Rosenfeld JB, Treuherz S. Elevation of serum potassium during beta-blockade: absence of relationship to renin-aldosterone system. Clin Pharmacol Ther. 1980; 28:765-768.
45. Steiness E. Negative potassium balance during beta blocker treatment of hypertension. Clin Pharmacol Ther. 1982;31:691-694.
46. Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs, part 1: pharmacodynamic and pharmacokinetic properties. Am Heart J. 1979;97:663-670.
47. Jackson G, Thirkettle JC, Taylor DJ, et al. A double-blind crossover trial of atenolol, enalapril and the fixed combination of atenolol and nifedipine in mild and moderate hypertension. Br J Clin Pract. 1993;47:66-70.
48. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Arch Intern Med. 1994;154:737-743.
49. Chrysant SG, Fox AAL, Stimpel M. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low-dose hydrochlorothiazide in hypertensive patients. Am J Hypertens. 1995;8:418-421.
50. Chrysant SG, Fagan T, Glazer R, Kriggman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:17-24.
51. Chrysant SG. Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension: a multicenter study. J Clin Pharmacol. 1997;37:47-52.
52. Ambrosioni E, Borghi C, Costa FU. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol. 1987;23:43S-50S.
53. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1987;9 (suppl 3):S36-S42.
54. Brown CL, Backhouse CI, Grippat JC, Santoni JPH. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 1990; 39:327-332.
55. Holland OB, Kuhnert L, Campbell WB, Anderson RJ. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension. 1983;5:235-239.
56. Chrysant SG, Danisa K, Kem DC, Smith WJ, Dillard BL, Frohlich ED. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension. 1979;1:136-141.
57. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;15:133-141.
58. Weinberger MH. Angiotensin-converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol. 1989; 13(suppl 3):1-4.
59. LaCourciere Y, Gagne C. Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension. J Hum Hypertens. 1993; 7:149-152.
60. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic neuropathy. N Engl J Med. 1993;329:1456-1462.
61. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-980.
62. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-erzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
63. Levy BI, Michel JB, Salzmann JL, et al. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res. 1998; 23:227-239.
64. Sihm I, Schroeder AP, Aalkjaer C, et al. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor based regimen in hypertensive patients. Am J Cardiol. 1995;76: 38E-40E.
65. Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis. Hypertension. 1996;28:269-275.
66. Frishman WH, Ram CVS, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel group study. J Clin Pharmacol. 1995;35: 1060-1066.
67. Cappuccio FP, Markandu ND, Singer DRJ, MacGregor GA. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens. 1993;11:839-848.
68. Morgan T, Anderson A, Hooper J. Enalapril and nifedipine in essential hypertension: synergism of the hypotensive effects in combination. Clin Exp Hypertens. 1988;10:779-789.
69. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic man: importance of therapeutic selection. Kidney Int. 1992; 41:912-919.
70. ter Wee PM, Epstein M. Angiotensin-converting enzyme inhibitors and progression of nondiabetic chronic renal disease. Arch Intern Med. 1993;153:1749-1759.
71. ter Wee PM, DeMichelli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic renal disease. Arch Intern Med. 1994;154:1185-1202.
72. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension: Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol. 1997;15:431-435.
73. Applegate WB, Cohen JD, Wolfson P, et al. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Am J Cardiol. 1996;78:58-65.
74. White WB, Viadero JJ, Lane TJ, Podesla S. Effects of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther. 1986;39:43-48.
75. Eggersten R, Svensson A, Dahlof B, Hansson L. Additive effect of isradipine in combination with captopril in hypertensive patients. Am J Med. 1989;86(4A):124-126.
76. Viskoper RJ, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. Curr Ther Res. 1997;58:331-342.
77. Maclean D. Combination therapy with amlodipine and captopril for resistant systemic hypertension. Am J Cardiol. 1994;73:55A-58A.
78. Jensen H, Garsdal P, Davis J. Amlodipine with enalapril therapy in moderate-severe essential hypertension. J Hum Hypertens. 1990;4:541-545.
79. Chrysant SG, Gavras H, Niederman AL, Marbury TC, Goldstein R. Clinical utility of long-term enalapril/diltiazem ER in stage 3-4 essential hypertension. J Clin Pharmacol. 1997;37: 810-815.
80. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45: 205-251.
81. DeCarvallo JGR, Dunn FG, Kem DC, Chrysant SG, Frohlich ED. Hemodynamic correlates of saralosin-induced arterial pressure changes. Circulation. 1978;57:373-378.
82. Kem DC, Frohlich ED, DeCarvallo JGR, et al. Hemodynamic correlates of saralosin responsiveness to hypertension. Kidney Int. 1979;155 (suppl 9):68-74.
83. Weber MA, Byyny RL, Pratt H, et al. Blood pressure effects of the angiotensin II receptor blocker losartan. Arch Intern Med. 1995;155:405-411.
84. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
85. Mackay JH, Arcuri KE, Goldberg AI, Snappin SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278-285.
86. Dunlay MC, FitzpatrickV, Chrysant SG, Francischetti EA, Goldberg AI, Sweet CS. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995;9:861-867.
87. Chrysant SG, Holtzman J, Lewin A, et al. Results of a pilot dose-ranging trial of valsartan in patients with essential hypertension [abstract]. Am J Hypertens. 1996;9:121A. Abstract G9.
88. Littlejohn T III, Saini R, Kassler-Taube KB, Chrysant SG, Marbury T. Long-term safety and efficacy of irbesartan (up to 300 mg) in hypertension [abstract]. Am J Hypertens. 1998;11: 101A. Abstract E024.
89. Black H, Reed J, Fitzimmons S, Shi Y. The combination of valsartan and hydrochlorothiazide is effective and well tolerated in essential hypertension [abstract]. Am J Hypertens. 1998;11: 70A. Abstract D006.
90. Chrysant SG, Chrysant C, Trus J, Hitchcock A. Antihypertensive effectiveness of amlodipine added to hydrochlorothiazide therapy in essential hypertension. Am J Hypertens. 1989;2:537-541.
91. Chrysant SG, Stimpel M. A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide. J Clin Pharmacol. 1996;36:701-706.
92. Nicholson JP, Resnick LM, Laragh JH. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Arch Intern Med. 1989;149:125-128.
93. Chrysant SG, Black HR, Davidov M, et al. Experience with terazosin administered in combination with other antihypertensive agents. Am J Med. 1986;80(5B):55-61.
94. Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995;154:110-115.
95. Ames RP, Chrysant SG, Gonzales F, et al. Effectiveness of doxazosin in systemic hypertension. Am J Cardiol. 1989;64:203-208.
96. Gordon AJ, Woeltjen AE. Treatment of essential hypertension with single daily doses of a prazosin-polythiazide combination: a multicentre study with Minizide. J Intern Med Res. 1981;9:303-308.
97. Whitsett TL, Chrysant SG, Dillard BL, Anton AH. Abrupt cessation of clonidine administration: a prospective study. Am J Cardiol. 1978;41:1285-1290.
98. Chrysant SG, Whitsett TL. Withdrawal of antihypertensive therapy. JAMA. 1978;239:2241.
99. Mroczek WJ, Lee WR, Davidov ME, Finnerty FA Jr. Clonidine and chlorthalidone (Combipres) in hypertension. Curr Ther Res Clin Exp. 1975;17: 47-53.
100. McMahon FG. Efficacy of an antihypertensive agent: comparison of methyldopa and hydrochlorothiazide in combination and singly. JAMA. 1975;231:155-158.